Solid Biosciences Inc. — Director's Dealing 2023

Jan 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2023-01-03

Reporting Person: SMITH IAN F (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-03	Common Stock	M	1620	—	Acquired	37670	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-03	Restricted Stock Units	$	M	1620	Disposed		Common Stock (1620)	Direct
2023-01-03	Stock Option (Right to Buy)	$5.62	M	70796	Acquired	2033-01-03	Common Stock (70796)	Direct
2023-01-03	Restricted Stock Units	$	A	62278	Acquired		Common Stock (62278)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: The restricted stock units were granted on January 3, 2022 and vested in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant.

F3: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

F4: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs").